Meto review

Meto starts with labs, then a clinician reviews a peptide protocol. Its public catalog lists GHK-Cu at $135 a month and CLARIFY at $395, alongside NAD⁺ at $210 and sermorelin at $120. Medication is separate from a $29 monthly membership, and its $149 Peptide Readiness Panel is needed unless recent labs are accepted. The membership page advertises Recovery Stack from $189, while the protocol index says Recovery & Joint is $249; confirm which applies. Meto says dashboard cancellation is immediate, but its terms do not refund the current membership period. The pharmacy is described as 503A without a name, and state restrictions are not listed.

Meto is a labs-gated compounded peptide platform. Its catalog runs four lab-matched stacks (GI Support, Muscle Preservation, Recovery and Joint, and Comprehensive Support), three higher-intensity formulations (RENEW for repair, CLARIFY for cognition and longevity, and SCULPT for body composition, the last flagged as unavailable), and ten à la carte lines: BPC-157, TB-500, sermorelin, NAD⁺, glutathione, GHK-Cu, thymosin α-1, epitalon, tesamorelin and a compounded GLP-1 family of semaglutide and tirzepatide. Care runs through independent licensed clinicians, and medication is compounded by 503A pharmacies described as FDA-registered, batch-tested by an independent lab and shipped cold-chain. Do not expect insurance: no insurance model appears anywhere on the site, and you pay the membership and medication yourself.

Labs first, and the site is unusually direct about why: a two-minute questionnaire cannot see your inflammation, your metabolic markers or your growth-hormone axis, and a blood panel can. The sequence is a $149 Peptide Readiness Panel, or an upload of recent labs, then a protocol match, then a licensed clinician reads the file and signs off, usually within 24 hours, then cold-chain delivery in three to five days. Membership adds a video consult every 90 days, unlimited secure messaging, weekly symptom logging with quarterly labs streaming to the clinician, protocol adjustments without a separate visit fee, and member pricing typically stated as 15 to 25 percent below the à la carte rate. Pausing keeps your chart open for six months. This is a better-designed clinical loop than the category norm. The disclosure gaps are specific: no LegitScript or PCAB certification is displayed, the compounding pharmacy is named only by category, the clinician network is said to cover 50 states with no list, no medical leadership is identified, and the site displays its own aggregate ratings and patient counts, which we do not repeat. The SCULPT formulation, which pairs MOTS-c with tesamorelin, is flagged as not currently available while awaiting FDA regulatory action.

Membership is $29 a month and medication is billed separately. The protocol index lists BPC-157 $85, glutathione $95, sermorelin $120, GHK-Cu $135, TB-500 $135, thymosin α-1 $140, epitalon $165, NAD⁺ $210 and tesamorelin $295 per month. It lists GI Support $175, Muscle Preservation $199, Recovery & Joint $249, Comprehensive Support $319, and both RENEW and CLARIFY $395 per month. The membership page instead says Recovery Stack from $189; these public figures conflict. SCULPT is marked unavailable.

Add $29 monthly membership to a chosen medication price. A $149 Peptide Readiness Panel is needed first unless the clinician accepts recent labs, so a $85 BPC-157 first month would total $263 if that panel is required ($149 + $29 + $85); later monthly cost would be $114 at the posted rates. The site does not clearly render an annual membership debit. Shipping is described as included. Dashboard cancellation is said to take effect immediately for future periods, but the terms do not refund the current membership period. Confirm state eligibility and the selected total before paying.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Meto's own footer states that compounded medications and therapies available through it have not been approved by the FDA, that the FDA does not evaluate compounded medications for safety or efficacy, and that use involves known and unknown risks that vary from patient to patient, a full and clearly written disclosure. It states 503A FDA-registered compounding and independent batch testing, but does not name the pharmacy or the testing lab. The catalog is not one thing on evidence, and the differences matter more than the price differences. Sermorelin and tesamorelin both act on the growth-hormone axis: sermorelin is a GHRH analog with a real mechanism and thin long-term outcome data, while tesamorelin is a stabilized GHRH analog that is genuinely FDA-approved, but only for visceral fat reduction in HIV-associated lipodystrophy; prescribed for anything else, it is off-label use of an approved drug. BPC-157 and TB-500 have interesting animal literature on soft-tissue and gut repair and essentially no controlled human outcome trials. GHK-Cu is a copper-binding tripeptide with a laboratory story in collagen synthesis and no controlled human outcome data behind the skin claims. Glutathione has essentially none. Injected NAD⁺ has no controlled human outcome trials; the oral precursors NR and NMN raise blood NAD⁺, a biomarker rather than an outcome. Individual results vary.